Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
PT Brigit Biofarmaka Teknologi Tbk
OBAT
Sector: Healthcare
Industry: Pharmaceuticals
Sub Sector: Pharmaceuticals & Health Care Research
Sub Industry: Pharmaceuticals
Live quote
tidak tersedia
Highlight Keuangan (2026 Q2) (In Rp)
EPS
22
ROE
10,67%
ROA
8,91%
Book Value
202
Net Income
7,32 M
Total Sales
89,01 M
Total Assets
164,25 M
DER
0.16x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
16,67%
Individual · Lokal
Individual · Lokal
Individual · Lokal
Individual · Lokal
Corporate · Lokal
Individual · Lokal
Corporate · Lokal
Individual · Lokal
Tentang Perusahaan
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Produk & Lini Bisnis
The business activities carried out by the Company are in the herbal makloon-medicinal (industry natural ingredients), cosmetics, as well as functional and botanical drinks
Dewan Direksi
IH
Is Heriyanto, SH
President Director
AS
Atik Setyaningsih
Director
AA
Angga Arie Wibowo
Director
Dewan Komisaris
ML
Machmud Lutfi Huzain
President Commissioner
NR
Narno Raharjo
Commission
DI
Dahlan Iskan
Independent Commission
Anak Usaha & Afiliasi
NamaDomisili%
PT. Meilis Inovasi Bioteknologi
Retail trade in cosmetics for humans
Sukoharjo 51.00%
PT. Botryo Herba Bioteknologi
Retail trade in cosmetics for humans, traditional medicines, soap and household cleaning materials, medical devices
Sukoharjo 51.00%
PT. Denbo Higienis Laboratoris
Soap industry and household cleaning materials
Sukoharjo 99.90%
PT. Algaepark Indonesia Mandiri
Soft drink industry, raw material industry for traditional medicine for humans, powdered and condensed milk processing industry, syrup industry, and glucose industry and the like Regency
Klaten 51.00%
Trend Keuangan (5 periode terakhir) — hover bar untuk detail
Total Sales Net Income (+) Net Income (-)
160jt 120jt 80jt 40jt 0 Sales 2025Q2: Rp 76.564.918 Net Income 2025Q2: Rp 17.797.705 2025Q2 Sales 2025Q3: Rp 114.747.227 Net Income 2025Q3: Rp 20.174.075 2025Q3 Sales 2025Q4: Rp 160.118.097 Net Income 2025Q4: Rp 22.641.939 2025Q4 Sales 2026Q1: Rp 43.823.271 Net Income 2026Q1: Rp 1.988.579 2026Q1 Sales 2026Q2: Rp 89.005.963 Net Income 2026Q2: Rp 7.319.165 2026Q2
2025 Q2
EPS 59
ROE 33,46%
2025 Q3
EPS 45
ROE 24,84%
2025 Q4
EPS 36
ROE 21,18%
2026 Q1
EPS 13
ROE 5,80%
2026 Q2
EPS 22
ROE 10,67%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
PeriodeTotal SalesNet IncomeTotal AssetsTotal EquityEPSROEDER
2026 Q2 89,01 M 7,32 M 164,25 M 137,24 M 22 10,67% 0.16x
2026 Q1 43,82 M 1,99 M 166,18 M 137,05 M 13 5,80% 0.18x
2025 Q4 160,12 M 22,64 M 131,00 M 106,93 M 36 21,18% 0.20x
2025 Q3 114,75 M 20,17 M 137,21 M 108,30 M 45 24,84% 0.21x
2025 Q2 76,56 M 17,80 M 135,94 M 106,38 M 59 33,46% 0.25x
Trend Harga Penutupan & Book Value — hover titik untuk detail
Close Price Book Value
478 398 317 237 157 Book Value 2025Q2: Rp 177 Close 2025Q2: Rp 340 2025Q2 Book Value 2025Q3: Rp 179 Close 2025Q3: Rp 450 2025Q3 Book Value 2025Q4: Rp 171 Close 2025Q4: Rp 388 2025Q4 Book Value 2026Q1: Rp 219 Close 2026Q1: Rp 348 2026Q1 Book Value 2026Q2: Rp 202 Close 2026Q2: Rp 230 2026Q2
2025 Q2
Close 340
BV 177
ROA 26,18%
2025 Q3
Close 450
BV 179
ROA 19,60%
2025 Q4
Close 388
BV 171
ROA 17,28%
2026 Q1
Close 348
BV 219
ROA 4,79%
2026 Q2
Close 230
BV 202
ROA 8,91%
History Harga Penutupan & Book Value
TahunQrtClose Price (Rp)Book Value (Rp)ROA
2026 2 230 202 8,91%
2026 1 348 219 4,79%
2025 4 388 171 17,28%
2025 3 450 179 19,60%
2025 2 340 177 26,18%
Data diperbarui pada: 2026-05-12 11:29:22